In short
A clinical trial is currently investigating JNJ-75276617, a promising new drug for pediatric and young adult patients with relapsed or refractory acute leukemias that have specific genetic alterations (KMT2A, NPM1, or nucleoporin). This Phase I/Ib study aims to determine the optimal dosage of JNJ-75276617 when combined with conventional chemotherapy. The trial focuses on patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and acute leukemia of ambiguous lineage who haven't responded adequately to previous treatments. By testing different dosages and monitoring safety, researchers hope to find effective treatment options for these challenging cases of leukemia.
Key points
- JNJ-75276617 is being investigated in a clinical trial for children and young adults with relapsed or refractory acute leukemias that have specific genetic alterations. The study aims to determine the optimal dose of this oral medication when combined with standard chemotherapy drugs. The trial includes patients with different types of acute leukemia (AML, ALL, and ambiguous lineage) and has separate treatment arms for those under 2 years old and those 2 years or older. Researchers are primarily focused on assessing the safety of the treatment combination while also measuring how effectively it fights cancer cells. This targeted approach represents a potential new treatment option for leukemia patients who haven't responded well to other therapies.
At a glance
- Drug Name
- JNJ-75276617
- Type of Study
- Phase I/Ib clinical trial
- Target Population
- Pediatric and young adult patients with relapsed/refractory acute leukemias harboring KMT2A, NPM1, or nucleoporin gene alterations
- Conditions Studied
- Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Acute Leukemia of Ambiguous Lineage
- Study Design
- Two parts: Dose Escalation (Part 1) and Dose Expansion (Part 2)
- Age Groups
- Two arms: <2 years old and ≥2 years old
- Administration
- JNJ-75276617 given orally; conventional chemotherapy drugs administered intravenously
- Combination Therapies
- For AML: Fludarabine, Cytarabine, Intrathecal Chemotherapy; For B-cell ALL: Dexamethasone, Vincristine, Pegaspargase, Intrathecal Chemotherapy
- Primary Outcomes
- Safety assessment (adverse events and their severity), Dose-limiting toxicity
- Secondary Outcomes
- Pharmacokinetics, Effects on leukemic blasts, Response rates, Time to response, Duration of response, Progression to stem cell transplantation
- Follow-up Period
- Up to 3 years and 5 months
What is JNJ-75276617?
JNJ-75276617 is an investigational drug being studied for the treatment of certain types of acute leukemia in children and young adults. This medication is specifically designed to target leukemias with specific genetic alterations, including changes in genes called KMT2A (also known as MLL), NPM1, or nucleoporin genes. These genetic changes are known to play important roles in the development of certain types of leukemia.
The drug is currently being investigated in clinical trials and is not yet approved for general use. It represents a targeted approach to leukemia treatment, focusing on specific genetic features of cancer cells rather than attacking all rapidly dividing cells as traditional chemotherapy does.
What Types of Leukemia Does JNJ-75276617 Target?
JNJ-75276617 is being studied for several types of acute leukemia, including:
- Acute Myeloid Leukemia (AML) - A type of cancer that affects the bone marrow and blood, starting in cells that would normally develop into different types of blood cells
- Acute Lymphoblastic Leukemia (ALL) - A cancer of the blood and bone marrow that affects white blood cells called lymphocytes
- Acute Leukemia of Ambiguous Lineage - A rare type of leukemia that shows features of both myeloid and lymphoid cells, making it difficult to classify
Importantly, the drug specifically targets leukemias that have alterations in certain genes, including KMT2A, NPM1, or nucleoporin genes. These genetic changes can drive the development and growth of leukemia cells.
How Does JNJ-75276617 Work?
JNJ-75276617 appears to work by targeting the interaction between a protein called menin and the KMT2A (also known as MLL) protein. In certain types of leukemia, this interaction contributes to the growth and survival of cancer cells.
The medication is designed to disrupt this interaction, which may lead to:
- Depletion of leukemic blasts - Reduction in the number of immature cancer cells
- Differentiation of leukemic blasts - Helping cancer cells to mature into normal blood cells
- Changes in expression of KMT2A target genes - Altering the activity of genes that are controlled by the KMT2A protein
By targeting these specific molecular mechanisms, JNJ-75276617 represents a more precise approach to treating leukemia compared to conventional chemotherapy.
Current Clinical Trial Information
JNJ-75276617 is currently being studied in a Phase I/Ib clinical trial for pediatric and young adult patients with relapsed or refractory acute leukemia. "Relapsed" means the leukemia has returned after initial treatment, while "refractory" means the cancer hasn't responded adequately to previous treatments.
The study has two main parts:
- Dose Escalation (Part 1): To determine the recommended Phase 2 dose(s) of JNJ-75276617 when used in combination with conventional chemotherapy
- Dose Expansion (Part 2): To further evaluate the safety of JNJ-75276617 at the recommended dose, both in combination with chemotherapy and as a standalone treatment in select patients with a low burden of disease
The trial includes two age groups:
- Arm A: Patients less than 2 years old
- Arm B: Patients 2 years and older
The starting doses are based on previous adult studies, with adjustments made according to age.
How JNJ-75276617 is Administered
JNJ-75276617 is administered orally (taken by mouth) on a 28-day cycle. This makes it more convenient than medications that must be given by injection or intravenous infusion.
The exact dosage depends on several factors, including:
- The patient's age
- How well the medication is tolerated
- Results from ongoing assessments during the trial
Researchers are carefully evaluating different dose levels to find the optimal amount that provides therapeutic benefit while minimizing side effects.
Combination Therapy Approach
In the clinical trial, JNJ-75276617 is being used in combination with conventional chemotherapy drugs, which differs based on the type of leukemia:
For patients with Acute Myeloid Leukemia (AML), the combination includes:
- Fludarabine - Given as an intravenous (IV) infusion
- Cytarabine - Given as an IV infusion
- Intrathecal chemotherapy - Medication delivered directly to the fluid surrounding the brain and spinal cord
For patients with B-cell Acute Lymphoblastic Leukemia (ALL), the combination includes:
- Dexamethasone - A steroid medication given as an IV infusion
- Vincristine - Given as an IV infusion
- Pegaspargase - Given as an IV infusion
- Intrathecal chemotherapy - As described above
Using JNJ-75276617 in combination with these established chemotherapy drugs may potentially enhance the overall effectiveness of treatment.
Expected Treatment Outcomes
While the clinical trial is still ongoing, researchers are measuring several outcomes to evaluate the effectiveness of JNJ-75276617:
- Overall Response Rate (ORR) - The percentage of patients whose cancer shrinks or disappears after treatment
- Time to Response (TTR) - How quickly patients respond to the treatment
- Duration of Response (DOR) - How long the response lasts before the cancer progresses again
- Percentage of patients who can proceed to stem cell transplantation - An important goal for many patients with acute leukemia
For patients with AML, a complete response might include complete remission (CR), complete remission with incomplete hematologic recovery (CRi), or complete remission with partial hematologic recovery (CRh).
For patients with B-cell ALL, response is measured as complete remission (CR) or complete remission with incomplete hematologic recovery (CRi).
Safety Monitoring and Side Effects
As with any investigational treatment, monitoring for side effects is a crucial part of the JNJ-75276617 clinical trial. Researchers are carefully tracking:
- Adverse Events (AEs) - Any unfavorable and unintended signs, symptoms, or diseases that occur during the trial
- Severity of AEs - Rated on a scale from Grade 1 (mild) to Grade 5 (death)
- Dose-Limiting Toxicities (DLTs) - Specific side effects that may limit how much of the drug can be given safely
The trial includes a dedicated period (the first 28-day cycle) to specifically monitor for DLTs. This helps researchers determine the maximum safe dose for future studies.
Since this is an early-phase trial, comprehensive information about all possible side effects is still being collected. Patients in the trial are closely monitored with regular medical assessments, blood tests, and other evaluations to ensure safety.